Bong-sook Baek

Array ( [id] => 17441770 [patent_doc_number] => 20220062275 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-03-03 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/095256 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091244 [patent_doc_number] => 20220409585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => TREATMENT OF AUTOINFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 17/775230 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003457 [patent_doc_number] => 20220362223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ORAL FORMULATION OF X842 [patent_app_type] => utility [patent_app_number] => 17/774207 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627414 [patent_doc_number] => 20210046067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/087890 [patent_app_country] => US [patent_app_date] => 2020-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17087890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18196689 [patent_doc_number] => 20230050208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/772878 [patent_app_country] => US [patent_app_date] => 2020-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186201 [patent_doc_number] => 20240165114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => TREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATOR [patent_app_type] => utility [patent_app_number] => 17/773274 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056256 [patent_doc_number] => 20220387342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => TRANSDERMAL PATCH [patent_app_type] => utility [patent_app_number] => 17/770369 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17043778 [patent_doc_number] => 11096937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/075189 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 63572 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156051 [patent_doc_number] => 20240148758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES [patent_app_type] => utility [patent_app_number] => 17/769398 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170804 [patent_doc_number] => 20240156778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/769344 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853412 [patent_doc_number] => 20210154157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => STABILIZATION OF EPINEPHRINE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/072126 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170804 [patent_doc_number] => 20240156778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/769344 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077291 [patent_doc_number] => 20220402903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => ISOXAZOLINE COMPOUND WITH OPTICAL ACTIVITY AND USE [patent_app_type] => utility [patent_app_number] => 17/754970 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981087 [patent_doc_number] => 20220347123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => COMBINATIONS OF GABA-A RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND NMDA ANTAGONISTS, NMDA NEGATIVE ALLOSTERIC MODULATORS OR NMDA PARTIAL AGONISTS [patent_app_type] => utility [patent_app_number] => 17/765975 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581412 [patent_doc_number] => 20210015814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/061047 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16741975 [patent_doc_number] => 10966941 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/039551 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 63598 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091233 [patent_doc_number] => 20220409574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => USE OF GINKGOLIDE A IN THE TREATMENT OF AUTISM [patent_app_type] => utility [patent_app_number] => 17/773213 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020843 [patent_doc_number] => 20210244714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASE [patent_app_type] => utility [patent_app_number] => 17/024016 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648679 [patent_doc_number] => 10925833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Extended release compositions comprising pyridostigmine [patent_app_type] => utility [patent_app_number] => 17/003323 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 29 [patent_no_of_words] => 35381 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523644 [patent_doc_number] => 20200397724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/003777 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003777 [rel_patent_id] =>[rel_patent_doc_number] =>)